Coya Therapeutics Added to MSCI USA Micro Cap Index

Coya Therapeutics, Inc. (NASDAQ: COYA), a biotechnology company focused on the development of biologics to enhance the function of regulatory T cells (Tregs), has been selected for inclusion in the MSCI USA Micro Cap Index. This change will take effect at the close of the market on May 31, 2024. The MSCI USA Micro Cap Index includes over 1,100 companies, with an average market capitalization of $122 million as of April 30, 2024. Various micro-cap ETFs track this index and are expected to adjust their portfolios accordingly.

Howard Berman, Ph.D., CEO of Coya, expressed his pride in the company's achievements, citing the inclusion as a testament to the team’s strategic focus and execution. He emphasized Coya’s commitment to developing treatments for neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia, Alzheimer’s, and Parkinson’s diseases. Berman also hinted at significant milestones expected throughout the remainder of 2024 that could contribute positively to the company’s narrative.

MSCI, a prominent provider of decision support tools and services for the global investment community, boasts over 45 years of expertise in research, data, and technology. They offer solutions that help clients make better investment decisions by understanding key drivers of risk and return.

Coya Therapeutics, headquartered in Houston, Texas, focuses on treatments based on the therapeutic potential of Tregs. Dysfunctional Tregs are implicated in various conditions, including neurodegenerative, metabolic, and autoimmune diseases. This cellular dysfunction can lead to chronic inflammation and oxidative stress, disrupting the immune system's balance.

The company’s investigational pipeline aims to restore the anti-inflammatory and immunomodulatory functions of Tregs using multiple therapeutic modalities. These include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. Coya’s lead product, COYA 302, combines COYA 301 (proprietary LD IL-2) and CTLA4-Ig for subcutaneous administration. This innovative product is designed for the treatment of ALS, Frontotemporal Dementia, Parkinson’s disease, and Alzheimer’s disease. By enhancing Tregs' anti-inflammatory functions and reducing pro-inflammatory factors, COYA 302 aims to restore immune balance and reduce inflammation sustainably.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!